Could Common Heart Meds Lower Prostate Cancer Risk?

FRIDAY, May 3, 2019 -- Good news for men: That blood pressure medication you're taking might be doing double duty, helping reduce your risk of developing prostate cancer, a new study shows. Researchers found that a beta blocker called atenolol cut...
Source: - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Conditions:   Prostate Adenocarcinoma;   Obesity, Morbid Interventions:   Device: Bead Block 300-500 um;   Behavioral: Weight Management;   Drug: Lupron Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Maryland Cigarette Restitution Fund Not yet recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSION: The use of PHI may considerably improve the accuracy of PCa detection in patients with elevated PSA and thus reduce the number of unnecessary biopsies. PMID: 32228820 [PubMed - in process]
Source: Central European Journal of Public Health - Category: International Medicine & Public Health Tags: Cent Eur J Public Health Source Type: research
Publication date: Available online 31 March 2020Source: Actas Urológicas Españolas (English Edition)Author(s): D. Nieblas-Toscano, A.J. Arenas-Bonilla, J.F. Flores-Martín, F. Gutiérrez-Tejero, C. Velarde-Muñoz, C.I. Ramos-Alaminos, M.C. Salas-Moreno, R. Galisteo-Moya, J. Moreno-Jiménez
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancerOral androgen receptor inhibitor (ARi) Nubeqa® (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profilemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Source: Toxicology Mechanisms and Methods - Category: Toxicology Authors: Source Type: research
Karine Mahéo Gaëlle Fromont The mechanisms underlying neuroendocrine (NE) differentiation in prostate cancer (PCa) remain mostly uncharacterized. Since a deregulated calcium homeostasis has been reported in neuroendocrine prostate cancer (NEPC), we explored herein the link between NE differentiation and the calcium-sensing receptor (CaSR). CaSR expression was evaluated by immunohistochemistry—together with NE markers—on tissue microarrays containing samples of normal prostate, localized PCa, metastatic castration resistant PCa (MCRPC) and NEPC. In prostate tissues, we observed a stro...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Ahmadianpour MV, Mowla J, Sotoodehnejadnematalahi F, Raheb J Abstract Studies on the blood of patients with prostate cancer using Dynamic Light Scattering (DLS) and corona protein size changes have shown that this test is highly specific and sensitive, but this method has not been studied in Iran, and therefore this study intends to perform this procedure using gold nanoparticles in prostate cancer detection. Blood samples of 60 male subjects aged 40-90 years were collected from 20 healthy, 20 benign and 20 prostate cancer patients. Optical scattering changes were measured by the level of gold nanoparticle...
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
Conditions:   Breast Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Metastatic Prostate Cancer Interventions:   Behavioral: In Person Counseling;   Behavioral: Educational Video Sponsors:   Dana-Farber Cancer Institute;   Ambry Genetics Not yet recruiting
Source: - Category: Research Source Type: clinical trials
We present a case of a 79 year old patient with a medical history of unilateral nerve-sparing radical prostatectomy due to a pT3aN0 (Gleason score 7) prostate carcinoma. Because of slightly elevated prostate specific antigen (PSA) level (0.35ng/dL), a fluorine-18-prostate specific membrane antigen (18F-PSMA)-1007 positron emission tomography/computed tomography (PET/CT) scan was performed, showing no signs of malignant recurrence. However, a moderately PSMA-avid nodular lesion was observed in the left occipital region with homogeneous contrast enhancement, suggestive for a meningioma, which was confirmed on magnetic resona...
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
CONCLUSION: Carbon-11-choline PET was found have a greater correlation with Gleason score than DWI and is considered to be more useful to predict a higher score in patients with prostate cancer. Fluorine-18-FDG PET was limited because of low sensitivity. PMID: 32222730 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
More News: Atenolol | Beta-Blockers | Cancer | Cancer & Oncology | Cardiology | General Medicine | Heart | Prostate Cancer | Study